No
Title
Name
Date
- 7 Therabest and Glycotope to assess Therabest’s iPSC-derived NK cell product TB-100 in combination with Glycotope’s GT-00AxIL15 immuno-cytokine for development in triple negative breast cancer THERABEST 2022-12-13
- 6 Reyon, Therabest to jointly develop pDNA sample supply business THERABEST 2022-11-24
- 5 THERABEST Announces Upcoming Presentation of Pre-clinical Data on imNK Cells for Alzheimer’s Disease at AAIC THERABEST 2022-07-28
- 4 [Publication] iPSCs in NK Cell Manufacturing and NKEV Development THERABEST 2022-07-08
- 3 THERABEST’s subsidiary moves into Japan’s medical industry city “Promoting iPS cell therapy partnerships” THERABEST 2022-06-29
- 2 [Publication] iPSC-Derived Natural Killer Cells for Cancer Immunotherapy THERABEST 2021-08-31
- 1 THERABEST, Strategy of New Drug Development Based on iPSC·Nano-Platform THERABEST 2020-09-14